5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
OwnerKathleen BATTISTA, Gilles Bignan +2inventors
InventorsKathleen BATTISTA, Gilles Bignan, Peter J. Connolly, Tina Morgan Ross
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful in the treatment of disorders and conditions mediated by the ORL-1 receptor. The present invention is further directed to processes for the preparation of said derivatives, pharmaceutical compositions comprising said derivatives and methods for the treatment of ORL-1 mediated disorders and conditions.
Claims21
A compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or an enantiomer, diastereoisomer, ester, prodrug, solvate or pharmaceutically acceptable salt thereof.
A process for the preparation of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or a pharmaceutically acceptable salt thereof;
- comprising
- reacting a compound of formula (II) with a compound of formula (III), wherein LG1 is a leaving group, in the presence of a base, in an organic solvent, to yield the corresponding compound of formula (IV);
- reacting the compound of formula (IV) with a compound of formula (V), wherein LG2 is a leaving group, in the presence of an inorganic base, in an organic solvent, to yield the corresponding compound of formula (VI);
- reacting the compound of formula (VI) with a compound of formula (VII), in an organic solvent, to yield the corresponding compound of formula (VIII);
- reacting the compound of formula (VIII) with a compound of formula (IX), wherein LG3 and LG4 are independently selected leaving groups, in an organic solvent, to yield the corresponding compound of formula (I).
A process for the preparation of a compound of formula (Ib)
- wherein
- R1 is selected from the group consisting of C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or a pharmaceutically acceptable salt thereof;
- comprising
- reacting a compound of formula (X) with a compound of formula (XI) wherein LG5 is a leaving group, in the presence of an inorganic base, in an organic solvent, to yield the corresponding compound of formula (Ib).
A process for the preparation of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or a pharmaceutically acceptable salt thereof;
- comprising
- reacting a compound of formula (XIII) with a compound of formula (V), wherein LG2 is a leaving group, in the presence of a base, in an organic solvent, to yield the corresponding compound of formula (XIV);
- reacting the compound of formula (XIV) with a compound of formula (VII), in an organic solvent, to yield the corresponding compound of formula (XV);
- reacting the compound of formula (XV) with a compound of formula (IX), wherein LG3 and LG4 are independently selected leaving groups, in an organic solvent, to yield the corresponding compound of formula (XVI);
- de-protecting the compound of formula (XVI), to yield the corresponding compound of formula (XVII);
- reacting the compound of formula (XVII) with a compound of formula (III), wherein LG1 is a leaving group, in the presence of a base, in an organic solvent, to yield the corresponding compound of formula (I).
A process for the preparation of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or a pharmaceutically acceptable salt thereof;
- comprising
- reacting a compound of formula (XVII) with a compound of formula (XII), in the presence of a reducing agent, in the presence of an acid, in an organic solvent, to yield the corresponding compound of formula (I).
A process for the preparation of a compound of formula (I)
- wherein
- R1 is selected from the group consisting of hydrogen, C1-4alkyl, —C1-4alkyl-OH and —C1-4alkyl-O—C1-4alkyl;
- R2 is phenyl;
- wherein the phenyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- m is an integer from 0 to 1;
- R3 is selected from the group consisting of cycloalkyl, partially unsaturated carbocyclyl, aryl and heteroaryl;
- wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, C1-4alkyl and C1-4alkoxy;
- or a pharmaceutically acceptable salt thereof;
- comprising
- reacting a compound of formula (IV) with a compound of formula (XIX), wherein LG6 is a leaving group, in the presence of a base, in an organic solvent, to yield the corresponding compound of formula (I).
Dependencies are inferred from the claim text.